{"id":"W3016397458","doi":"10.1111/bjd.19147","title":"Efficacy and safety of ixekizumab in a phase <scp>III</scp> , randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis ( <scp>IXORA</scp> ‐ <scp>PEDS</scp> )","year":2020,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":108,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"Cilag; UCB Pharma; Sanofi Genzyme; Genentech; Ortho Dermatologics; Gilead Sciences; LEO Pharma; Bausch Health; Astellas Pharma; Sanofi; Kyowa Hakko Kirin; Coherus Biosciences; Sun Pharma; Dermira; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Medac; Baxalta; Celgene; Pfizer; Biogen; Amgen; Meiji Seika Pharma; Galderma; Eli Lilly and Company; Bristol-Myers Squibb; Astellas Pharma US","keywords":"Ixekizumab; Placebo; Medicine; Psoriasis; Adverse effect; Psoriasis Area and Severity Index; Secukinumab; Internal medicine; Dermatology; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002536844,0.001284108,0.003008781,0.0003290266,0.0003870752,0.001019266,0.0009632339,0.001754384,0.003342835],"category_scores_gemma":[0.00169745,0.0007969387,0.001846278,0.0003457521,0.001267692,0.000735014,0.0002769608,0.002923321,0.0006297001],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006349746,"about_ca_system_score_gemma":0.001609941,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000628793,"about_ca_topic_score_gemma":0.0009185143,"domain_scores_codex":[0.9991509,0.0004476158,0.00006845262,0.0001446538,0.00009466238,0.00009362978],"domain_scores_gemma":[0.9986766,0.0003219846,0.0003982632,0.0001008009,0.00009664008,0.0004057321],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.943647,0.01466023,0.001374633,0.001084788,0.001133771,0.00009663933,0.0001116278,0.000419439,0.01424454,0.0001324132,0.001066608,0.02202818],"study_design_scores_gemma":[0.8869447,0.1090349,0.002175119,0.00002606714,0.0002848537,0.00006919663,0.00001184444,0.0002236723,0.0007696305,0.00003916315,0.0004122072,0.00000871354],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9876774,0.004673038,0.0008370609,0.0003949837,0.0003371131,0.004029993,0.0007462737,0.0001055524,0.001198618],"genre_scores_gemma":[0.9861287,0.003547509,0.002145819,0.0008568903,0.0004129012,0.004397566,0.001053875,0.00003081448,0.001426002],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003342835,"threshold_uncertainty_score":0.01341629,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01241096948153409,"score_gpt":0.2384729632929913,"score_spread":0.2260619938114572,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}